THE WIRE · № 65574
Zydus, MSN partner to Launch First Generic of Adempas® (Riociguat Tablets) in the U.S.
01 THE MACHINE READ
WHY IT MATTERS.
A first-to-market generic pressures branded riociguat pricing and the originator's PAH franchise revenue.
Generic entry erodes branded pulmonary hypertension pricing
Further generic approvals and payer formulary shifts
Limited US riociguat market size caps the drag
FULL DISPATCH
First-to-market launch brings a lower-cost riociguat to U.S. patients living with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension AHMEDABAD, India and PENNINGTON, N.J., Oct. 5, 2026 /PRNewswire/ -- Zydus Lifesciences Limited (Zydus), in partnership with...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
AHN Cardiology Department at Allegheny General Hospital Launches Clinical Trial Investigating New Therapy for Pulmonary Arterial Hypertension2026-10-05 17:45 UTC
IVD Quality Control Market to Reach US$ 2.2 Bn by 2031, Growing at 5.3% CAGR as Labs Shift to Automated QC Workflows: New Report by Wissen Research2026-10-05 18:01 UTC
CDU Heat Exchanger Antifoulants Market to Reach USD 270.24 Million by 20322026-10-05 18:46 UTC
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma2026-10-05 18:54 UTC
CPI | Invisalign Maker Must Face Renewed Antitrust Litigation2026-10-05 18:41 UTC
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.